Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25557486 | 0.95 | KDM4E (0.37) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL22696342 | 0.84 | FGFR1 (0.51) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL22696561 | 0.84 | TNK2 (0.37) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL22696560 | 0.84 | TNK2 (0.37) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL22696339 | 0.83 | MAPT (0.40) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL25557496 | 0.81 | RIPK1 (0.37) | FGFR1FGFR3NTRK1NTRK2TNK2 | |
| SCHEMBL25557510 | 0.81 | RIPK1 (0.35) | FGFR1FGFR3NTRK1NTRK2FGFR4 | |
| SCHEMBL25557491 | 0.80 | FGFR1 (0.47) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL25557483 | 0.79 | MAPT (0.38) | KDM4EALDH1A1MAPTMAOAMAOB | |
| SCHEMBL21050871 | 0.71 | FGFR1 (0.69) | FGFR1FGFR2FGFR3FGFR4TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2020236524-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | KDM4E 2504/4885ALDH1A1 2502/4885MAPT 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.